Cargando…

1727. Phase 1b Dose-ranging Study Demonstrates Tolerability and Pharmacokinetics (PK) of Oral Epetraborole at the Predicted Therapeutic Dosage for Mycobacterium avium Complex (MAC) Lung Disease

BACKGROUND: Epetraborole (EBO) — an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activity against nontuberculous mycobacteria — is under clinical development for treatment of MAC lung disease. We conducted a Phase 1b dose-ranging study of EBO tablets in healthy adu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eckburg, Paul B, Clarke, Dave, Long, Jennifer, Chanda, Sanjay, Krause, Kevin M, Easom, Eric, Talbot, George, Rubino, Christopher M, Molga, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752554/ http://dx.doi.org/10.1093/ofid/ofac492.1357

Ejemplares similares

2556. A Phase 1, Open-Label, Single Dose Study to Evaluate the Pharmacokinetics (PK), Safety, and Tolerability of Epetraborole Tablets and the Impact of Alcohol Dehydrogenase (ADH) Genotype on the PK of Epetraborole and Metabolite M3 in Healthy Japanese Adult Subjects
por: Patel, Gina, et al.
Publicado: (2023)

593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
por: Ganesan, Harish, et al.
Publicado: (2022)

2144. A Phase 1, Multicenter, Open-Label, Parallel-Group Study to Assess the Safety and Pharmacokinetics (PK) of Oral Epetraborole Tablets in Adult Subjects with Varying Degrees of Renal Function
por: Patel, Gina, et al.
Publicado: (2023)

2135. Epetraborole in vitro Activity Against Mycobacterium avium complex Recent Clinical Isolates from Japan
por: White, Tiffany Keepers, et al.
Publicado: (2023)

Epetraborole Is Active against Mycobacterium abscessus
por: Ganapathy, Uday S., et al.
Publicado: (2021)

Newton: 1642-1727
por: Westfall, Richard S
Publicado: (1994)

Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline
por: Sullivan, Jaryd R., et al.
Publicado: (2021)

Donald Monro (1727–1802)
Publicado: (1971)

Johannes Gessners Pariser Tagebuch 1727
por: Brockliss, Laurence
Publicado: (1986)

The History of the College Library 1688—1727
por: Payne, L. M., et al.
Publicado: (1971)

1704. Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Demonstrates Potent Efficacy and Improves Efficacy of Standard of Care Regimen Against Mycobacterium avium complex in a Chronic Mouse Lung Infection Model
por: De, Kavita, et al.
Publicado: (2022)

1716. In Vitro Drug-Drug Interaction Evaluation of Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor
por: Shafiee, Afshin, et al.
Publicado: (2022)

The impact of the epidemics of 1727-1730 in South West Worcestershire.
por: Johnston, J A
Publicado: (1971)

1697. Dose-response Studies of the Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Epetraborole, in the Intracellular Hollow Fiber System Model of Mycobacterium avium complex Lung Disease
por: Chapagain, Moti, et al.
Publicado: (2022)

Promoting experimental learning: experiment and the Royal Society 1660–1727
por: Clericuzio, Antonio
Publicado: (1992)

1727P COVID-19 pandemic: Impact on doctors in training
por: Farooq, A.R., et al.
Publicado: (2020)

2064. In Vitro Susceptibility of Recent Mycobacterium abscessus Isolates to Epetraborole (EBO) and Comparators by Broth Microdilution
por: Nguyen, Minh-Vu H, et al.
Publicado: (2023)

Chylothorax: A Late Complication of Disseminated Mycobacterium avium Complex (MAC) Infection
por: Jog, Abhishrut, et al.
Publicado: (2023)

La mina de San Juan de Rayas, 1670-1727
por: Rionda Arreguín, Isauro
Publicado: (1982)

A tale of two images: From mycobacterium avium complex-lung disease (MAC-LD) to mycobacterium avium complex-pleural disease()
por: Varkey, Mary Rithu, et al.
Publicado: (2021)

Opportunistic Pathogens Mycobacterium Avium Complex (MAC) and Legionella spp. Colonise Model Shower
por: Whiley, Harriet, et al.
Publicado: (2015)

1727. Sustained Antimicrobial Activity of a Novel Disinfectant Against Healthcare Pathogens
por: Rutala, William, et al.
Publicado: (2018)

Detection of Mycobacterium avium-intracellulare Complex (MAC) by Bronchial Lavage and the Relationship with Titers of Anti-Glycopeptidolipid-Core IgA Antibodies to MAC in Patients with Pulmonary MAC Disease
por: Shimada, Daishi, et al.
Publicado: (2023)

A Screening of the MMV Pandemic Response Box Reveals Epetraborole as A New Potent Inhibitor against Mycobacterium abscessus
por: Kim, Taeho, et al.
Publicado: (2021)

Role of Mycobacterium avium catalase-peroxidase (KatG) in the pathogenesis of MAC disease in HIV patients
por: Latawa, Romica, et al.
Publicado: (2012)

Population Structure and Local Adaptation of MAC Lung Disease Agent Mycobacterium avium subsp. hominissuis
por: Yano, Hirokazu, et al.
Publicado: (2017)

Characteristics of Mycobacterium avium complex (MAC) pulmonary disease in previously treated lung cancer patients()
por: Meier, Erin, et al.
Publicado: (2017)

MAC Attack: Clinical Correlates of Mycobacterium avium Complex Infection Among Patients With and Without Cancer
por: Gupta, Karan, et al.
Publicado: (2020)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data
por: Trang, Michael, et al.
Publicado: (2018)

Pulmonary Mycobacterium avium infection demonstrating unusual lobar caseous pneumonia
por: Okuzumi, Shinichi, et al.
Publicado: (2016)

Detection of Legionella, L. pneumophila and Mycobacterium Avium Complex (MAC) along Potable Water Distribution Pipelines
por: Whiley, Harriet, et al.
Publicado: (2014)

Pharmacokinetic/Pharmacodynamic (PK/PD) Simulation for Dosage Optimization of Colistin Against Carbapenem-Resistant Klebsiella pneumoniae and Carbapenem-Resistant Escherichia coli
por: Jitaree, Kamonchanok, et al.
Publicado: (2019)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

Formulation of a rational dosage regimen of ceftiofur hydrochloride oily suspension by pharmacokinetic-pharmacodynamic (PK-PD) model for treatment of swine Streptococcus suis infection
por: Luo, Wanhe, et al.
Publicado: (2021)

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
por: Bradley, John, et al.
Publicado: (2018)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Persimmon-derived tannin has bacteriostatic and anti-inflammatory activity in a murine model of Mycobacterium avium complex (MAC) disease
por: Matsumura, Yoko, et al.
Publicado: (2017)

Role of Toll-Like Receptor 4 in Mycobacterium avium subsp. paratuberculosis Infection of Bovine Mammary Epithelial (MAC-T) Cells In Vitro
por: Shandilya, Umesh K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6ta1ol7ofclaoklcet6hfhtgkd